Nystatin Dosing for Oral Thrush in Adults
For mild oral thrush in adults, use nystatin suspension 100,000 U/mL at 4–6 mL four times daily OR nystatin pastilles 200,000 U each, taking 1–2 pastilles four times daily, for 7–14 days. 1
Treatment Algorithm Based on Disease Severity
Mild Disease (First-Line Topical Options)
The IDSA guidelines provide strong recommendations with moderate-quality evidence for nystatin as an alternative agent for mild oropharyngeal candidiasis 1:
Nystatin Suspension:
- Dose: 4–6 mL of 100,000 U/mL suspension
- Frequency: Four times daily
- Duration: 7–14 days
- Administration: Swish in mouth and retain as long as possible before swallowing 1, 2
Nystatin Pastilles:
- Dose: 1–2 pastilles (200,000 U each)
- Frequency: Four times daily
- Duration: 7–14 days
- Administration: Allow to dissolve slowly in mouth 1
Moderate to Severe Disease
Nystatin is NOT recommended for moderate to severe oral thrush. Instead, oral fluconazole 100–200 mg daily for 7–14 days is the preferred treatment with strong recommendation and high-quality evidence 1.
Important Clinical Considerations
Formulation Superiority
Pastilles are more effective than suspension. Research demonstrates that nystatin pastilles maintain antifungal activity in the oral cavity for at least 5 hours, while suspension activity is eliminated rapidly 3. The pastille formulation achieves higher mycological cure rates compared to suspension alone 4. When feasible, prescribe pastilles over suspension for better outcomes 3.
Combination Therapy
Administering nystatin suspension and pastilles together for 2 weeks may achieve higher clinical and mycological cure rates than using suspension alone 4. This approach can be considered for patients with persistent mild disease.
Treatment Duration Optimization
Extending treatment to 4 weeks improves efficacy. Studies show that 4-week treatment courses with nystatin pastilles demonstrate better clinical efficacy than 2-week courses 4. For recalcitrant cases of mild disease, consider extending therapy beyond the standard 7–14 day duration.
Dosing Considerations
Higher pastille doses yield better results: nystatin pastilles at 400,000 IU produce significantly higher mycological cure rates than 200,000 IU doses 4. However, the standard IDSA-recommended dose remains 200,000 U per pastille 1.
Common Pitfalls and How to Avoid Them
Pitfall #1: Using nystatin for moderate-severe disease
- Nystatin has inferior efficacy compared to fluconazole in HIV/AIDS patients and those with more severe infections 5
- Always escalate to systemic fluconazole (100–200 mg daily) for moderate-severe cases 1
Pitfall #2: Inadequate contact time
- Patients must retain suspension in mouth as long as possible before swallowing 2
- Pastilles must dissolve slowly; instruct patients not to chew or swallow whole 6
Pitfall #3: Denture-related candidiasis
- Antifungal therapy alone is insufficient; denture disinfection is mandatory 1
- Failure to address dentures leads to treatment failure and rapid relapse
Pitfall #4: Expecting nystatin to match fluconazole efficacy
- At day 14, fluconazole achieves 87% clinical cure versus 52% with nystatin in HIV patients 5
- Fluconazole provides longer disease-free intervals (18% relapse vs 44% with nystatin at day 28) 5
- Reserve nystatin for mild disease or when systemic azoles are contraindicated
Safety Profile
Common adverse effects include poor taste and gastrointestinal reactions 4. Nystatin contains 0.5–1% alcohol by volume 2. The medication is generally well-tolerated with no severe adverse events reported in clinical trials 7.
Refractory Disease Management
If oral thrush fails to respond to nystatin after 7–14 days, do not continue nystatin. Escalate to:
- Oral fluconazole 100–200 mg daily for 7–14 days (first choice) 1
- For fluconazole-refractory disease: itraconazole solution 200 mg once daily OR posaconazole suspension 400 mg twice daily for 3 days then 400 mg daily 1
Special Populations
HIV-infected patients: Antiretroviral therapy is strongly recommended to reduce recurrent infections 1. For patients with CD4 counts <200 who are Candida albicans carriers with prior oral candidiasis history, prophylactic nystatin pastilles (200,000 U daily) can delay onset of oral candidiasis 8.